Dyne Therapeutics, Inc.
NASDAQ:DYNBiotechnology
+$0.38 today
- Market cap
- $3.00B
- Beta
- 1.08
- P/E (TTM)
- -7.2
- EPS (TTM)
- -$2.74
Volume 2.44M
Average 1.71M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Dyne Therapeutics, Inc.
NASDAQ:DYN
Intrinsic Alpha fair value
Locked
Current Price
$16.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | N/A5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
PTC Therapeutics, Inc. NASDAQ:PTCT | $5.30B | $63.49 | Undervalued | -35.0 | -23.72% |
Ionis Pharmaceuticals, Inc. NASDAQ:IONS | $4.84B | $29.06 | Not rated | -37.5 | -62.77% |
Stoke Therapeutics, Inc. NASDAQ:STOK | $1.75B | $26.68 | Undervalued | -11.1 | -3.58% |
Sarepta Therapeutics, Inc. NASDAQ:SRPT | $1.72B | $16.07 | Undervalued | 27.8 | -14.02% |
Solid Biosciences Inc. NASDAQ:SLDB | $763.42M | $6.84 | Not rated | -4.3 | +44.39% |
Wave Life Sciences Ltd. NASDAQ:WVE | $617.33M | $3.13 | Not rated | -6.6 | -59.76% |
Capricor Therapeutics, Inc. NASDAQ:CAPR | $551.90M | $9.53 | Not rated | -13.9 | +32.34% |
Larimar Therapeutics, Inc. NASDAQ:LRMR | $313.73M | $3.02 | Not rated | -1.8 | -4.45% |
PepGen Inc. NASDAQ:PEPG | $301.98M | $4.36 | Not rated | -1.6 | -22.79% |
Entrada Therapeutics, Inc. NASDAQ:TRDA | $199.28M | $5.09 | Not rated | -1.7 | -49.40% |
Continue the stock analysis
Jump to another research area for this company.